Evidence map›Paper›PMID 30588378›Full record

ArticleNeurology. Clinical practice2018

Status epilepticus alert reduces time to administration of second-line antiseizure medications.

Mauricio F Villamar, Aaron M Cook, Chenlu Ke, Yan Xu, Jordan L Clay, Katelyn S Dolbec, Rachel Ward-Mitchell, Larry B Goldstein, Meriem Bensalem-Owen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Clinical practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mauricio F VillamarDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Aaron M CookDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Chenlu KeDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Yan XuDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Jordan L ClayDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Katelyn S DolbecDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Rachel Ward-MitchellDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Larry B GoldsteinDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Meriem Bensalem-OwenDepartments of Neurology (MFV, JLC, KSD, RW-M, LBG, MB-O) and Statistics (CK, YX), University of Kentucky, Lexington; Department of Neurology (MFV), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and UK HealthCare Pharmacy Services (AMC), Lexington, KY.
Brigham and Women's Hospital · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatus epilepticus (SE) is a neurologic emergency with high morbidity and mortality. Delays in SE treatment are common in clinical practice and can be associated with poorer outcomes. Our goal was to determine whether the implementation of an SE alert protocol improves time to administration of a second-line antiseizure medication (ASM) in hospitalized adults.

methodsWe developed and implemented an inpatient SE alert system. A quasiexperimental cohort study was performed. We analyzed all patients aged 18-85 years who were managed at the University of Kentucky Medical Center using the SE alert protocol between March 2015 and June 2017 (n = 19). Controls were the first 20 consecutive patients treated for SE over the same time period, but who were managed with usual care (i.e., without SE alert protocol).

resultsTime to administration of a second-line ASM was shorter with the use of the SE alert system (22.21 ± 3.44 minutes) compared to usual care (58.30 ± 6.72 minutes;

conclusionImplementation of an SE alert system led to a marked improvement in time to administration of a second-line ASM. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for adult inpatients treated for SE, implementation of an SE alert protocol reduces time to administration of second-line ASM.

Identifiers

PMID30588378
PMCPMC6294531
OpenAlexW2894972723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.